LEMAITRE VASCULAR INC (LMAT) Fundamental Analysis & Valuation
NASDAQ:LMAT • US5255582018
Current stock price
109 USD
-1.85 (-1.67%)
At close:
109 USD
0 (0%)
After Hours:
This LMAT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. LMAT Profitability Analysis
1.1 Basic Checks
- LMAT had positive earnings in the past year.
- In the past year LMAT had a positive cash flow from operations.
- Each year in the past 5 years LMAT has been profitable.
- In the past 5 years LMAT always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 9.38%, LMAT belongs to the top of the industry, outperforming 89.13% of the companies in the same industry.
- LMAT has a better Return On Equity (14.67%) than 89.67% of its industry peers.
- LMAT has a better Return On Invested Capital (9.04%) than 86.96% of its industry peers.
- LMAT had an Average Return On Invested Capital over the past 3 years of 8.61%. This is in line with the industry average of 9.18%.
- The 3 year average ROIC (8.61%) for LMAT is below the current ROIC(9.04%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.38% | ||
| ROE | 14.67% | ||
| ROIC | 9.04% |
ROA(3y)8.68%
ROA(5y)8.37%
ROE(3y)12.61%
ROE(5y)11.22%
ROIC(3y)8.61%
ROIC(5y)8.85%
1.3 Margins
- LMAT has a better Profit Margin (23.13%) than 95.11% of its industry peers.
- In the last couple of years the Profit Margin of LMAT has grown nicely.
- LMAT has a Operating Margin of 27.21%. This is amongst the best in the industry. LMAT outperforms 96.20% of its industry peers.
- LMAT's Operating Margin has improved in the last couple of years.
- LMAT has a Gross Margin of 71.53%. This is amongst the best in the industry. LMAT outperforms 80.98% of its industry peers.
- In the last couple of years the Gross Margin of LMAT has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.21% | ||
| PM (TTM) | 23.13% | ||
| GM | 71.53% |
OM growth 3Y13.74%
OM growth 5Y4.46%
PM growth 3Y22%
PM growth 5Y7.14%
GM growth 3Y3.31%
GM growth 5Y1.81%
2. LMAT Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LMAT is destroying value.
- LMAT has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, LMAT has more shares outstanding
- Compared to 1 year ago, LMAT has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 8.85 indicates that LMAT is not in any danger for bankruptcy at the moment.
- LMAT has a Altman-Z score of 8.85. This is amongst the best in the industry. LMAT outperforms 86.96% of its industry peers.
- The Debt to FCF ratio of LMAT is 2.26, which is a good value as it means it would take LMAT, 2.26 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of LMAT (2.26) is better than 85.87% of its industry peers.
- A Debt/Equity ratio of 0.43 indicates that LMAT is not too dependend on debt financing.
- The Debt to Equity ratio of LMAT (0.43) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 2.26 | ||
| Altman-Z | 8.85 |
ROIC/WACC0.9
WACC10.05%
2.3 Liquidity
- A Current Ratio of 12.89 indicates that LMAT has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 12.89, LMAT belongs to the top of the industry, outperforming 97.28% of the companies in the same industry.
- A Quick Ratio of 10.95 indicates that LMAT has no problem at all paying its short term obligations.
- LMAT's Quick ratio of 10.95 is amongst the best of the industry. LMAT outperforms 96.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.89 | ||
| Quick Ratio | 10.95 |
3. LMAT Growth Analysis
3.1 Past
- LMAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.68%, which is quite impressive.
- The Earnings Per Share has been growing by 17.12% on average over the past years. This is quite good.
- LMAT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.53%.
- The Revenue has been growing by 14.04% on average over the past years. This is quite good.
EPS 1Y (TTM)22.68%
EPS 3Y36.78%
EPS 5Y17.12%
EPS Q2Q%38.78%
Revenue 1Y (TTM)13.53%
Revenue growth 3Y15.57%
Revenue growth 5Y14.04%
Sales Q2Q%15.68%
3.2 Future
- Based on estimates for the next years, LMAT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.37% on average per year.
- Based on estimates for the next years, LMAT will show a quite strong growth in Revenue. The Revenue will grow by 9.67% on average per year.
EPS Next Y20.86%
EPS Next 2Y15.35%
EPS Next 3Y12.89%
EPS Next 5Y11.37%
Revenue Next Year12.16%
Revenue Next 2Y10.55%
Revenue Next 3Y10.08%
Revenue Next 5Y9.67%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. LMAT Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 45.80, LMAT can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, LMAT is valued a bit cheaper than 67.93% of the companies in the same industry.
- LMAT is valuated expensively when we compare the Price/Earnings ratio to 25.73, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 37.89, the valuation of LMAT can be described as expensive.
- Based on the Price/Forward Earnings ratio, LMAT is valued a bit cheaper than 69.02% of the companies in the same industry.
- LMAT is valuated expensively when we compare the Price/Forward Earnings ratio to 23.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.8 | ||
| Fwd PE | 37.89 |
4.2 Price Multiples
- LMAT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 71.20% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, LMAT is valued a bit cheaper than 76.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.34 | ||
| EV/EBITDA | 25.58 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of LMAT may justify a higher PE ratio.
- A more expensive valuation may be justified as LMAT's earnings are expected to grow with 12.89% in the coming years.
PEG (NY)2.2
PEG (5Y)2.68
EPS Next 2Y15.35%
EPS Next 3Y12.89%
5. LMAT Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.94%, LMAT is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 0.22, LMAT pays a better dividend. On top of this LMAT pays more dividend than 91.85% of the companies listed in the same industry.
- With a Dividend Yield of 0.94, LMAT pays less dividend than the S&P500 average, which is at 1.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.94% |
5.2 History
- On average, the dividend of LMAT grows each year by 16.13%, which is quite nice.
- LMAT has paid a dividend for at least 10 years, which is a reliable track record.
- LMAT has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)16.13%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
- LMAT pays out 31.37% of its income as dividend. This is a sustainable payout ratio.
- The dividend of LMAT is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP31.37%
EPS Next 2Y15.35%
EPS Next 3Y12.89%
LMAT Fundamentals: All Metrics, Ratios and Statistics
109
-1.85 (-1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)04-29 2026-04-29
Inst Owners96.24%
Inst Owner Change7.54%
Ins Owners7.97%
Ins Owner Change-9.94%
Market Cap2.48B
Revenue(TTM)249.60M
Net Income(TTM)57.73M
Analysts78.82
Price Target105.74 (-2.99%)
Short Float %5.88%
Short Ratio6.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.94% |
Yearly Dividend0.8
Dividend Growth(5Y)16.13%
DP31.37%
Div Incr Years13
Div Non Decr Years13
Ex-Date03-12 2026-03-12 (0.25)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.9%
Min EPS beat(2)0.42%
Max EPS beat(2)7.38%
EPS beat(4)3
Avg EPS beat(4)1.52%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.19%
EPS beat(12)10
Avg EPS beat(12)5.13%
EPS beat(16)10
Avg EPS beat(16)-0.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.58%
Revenue beat(4)3
Avg Revenue beat(4)-0.13%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)5
Avg Revenue beat(8)-0.14%
Revenue beat(12)7
Avg Revenue beat(12)0.21%
Revenue beat(16)8
Avg Revenue beat(16)-0.25%
PT rev (1m)0%
PT rev (3m)-0.64%
EPS NQ rev (1m)7.1%
EPS NQ rev (3m)7.1%
EPS NY rev (1m)9.01%
EPS NY rev (3m)9.01%
Revenue NQ rev (1m)0.92%
Revenue NQ rev (3m)0.92%
Revenue NY rev (1m)2.72%
Revenue NY rev (3m)2.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.8 | ||
| Fwd PE | 37.89 | ||
| P/S | 9.95 | ||
| P/FCF | 33.34 | ||
| P/OCF | 30.56 | ||
| P/B | 6.31 | ||
| P/tB | 8.43 | ||
| EV/EBITDA | 25.58 |
EPS(TTM)2.38
EY2.18%
EPS(NY)2.88
Fwd EY2.64%
FCF(TTM)3.27
FCFY3%
OCF(TTM)3.57
OCFY3.27%
SpS10.96
BVpS17.27
TBVpS12.93
PEG (NY)2.2
PEG (5Y)2.68
Graham Number30.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.38% | ||
| ROE | 14.67% | ||
| ROCE | 11.72% | ||
| ROIC | 9.04% | ||
| ROICexc | 23.78% | ||
| ROICexgc | 43.2% | ||
| OM | 27.21% | ||
| PM (TTM) | 23.13% | ||
| GM | 71.53% | ||
| FCFM | 29.83% |
ROA(3y)8.68%
ROA(5y)8.37%
ROE(3y)12.61%
ROE(5y)11.22%
ROIC(3y)8.61%
ROIC(5y)8.85%
ROICexc(3y)18.5%
ROICexc(5y)16.17%
ROICexgc(3y)34.8%
ROICexgc(5y)32.81%
ROCE(3y)11.16%
ROCE(5y)11.48%
ROICexgc growth 3Y19.07%
ROICexgc growth 5Y8.49%
ROICexc growth 3Y27.82%
ROICexc growth 5Y16.94%
OM growth 3Y13.74%
OM growth 5Y4.46%
PM growth 3Y22%
PM growth 5Y7.14%
GM growth 3Y3.31%
GM growth 5Y1.81%
F-Score7
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 2.26 | ||
| Debt/EBITDA | 2.15 | ||
| Cap/Depr | 65.11% | ||
| Cap/Sales | 2.72% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.73% | ||
| Profit Quality | 128.99% | ||
| Current Ratio | 12.89 | ||
| Quick Ratio | 10.95 | ||
| Altman-Z | 8.85 |
F-Score7
WACC10.05%
ROIC/WACC0.9
Cap/Depr(3y)71.15%
Cap/Depr(5y)58.36%
Cap/Sales(3y)3.21%
Cap/Sales(5y)2.96%
Profit Quality(3y)103.77%
Profit Quality(5y)106.24%
High Growth Momentum
Growth
EPS 1Y (TTM)22.68%
EPS 3Y36.78%
EPS 5Y17.12%
EPS Q2Q%38.78%
EPS Next Y20.86%
EPS Next 2Y15.35%
EPS Next 3Y12.89%
EPS Next 5Y11.37%
Revenue 1Y (TTM)13.53%
Revenue growth 3Y15.57%
Revenue growth 5Y14.04%
Sales Q2Q%15.68%
Revenue Next Year12.16%
Revenue Next 2Y10.55%
Revenue Next 3Y10.08%
Revenue Next 5Y9.67%
EBIT growth 1Y29.96%
EBIT growth 3Y31.45%
EBIT growth 5Y19.13%
EBIT Next Year38.55%
EBIT Next 3Y19.89%
EBIT Next 5Y16.94%
FCF growth 1Y100.39%
FCF growth 3Y49.81%
FCF growth 5Y18.54%
OCF growth 1Y84.14%
OCF growth 3Y47.38%
OCF growth 5Y18.48%
LEMAITRE VASCULAR INC / LMAT Fundamental Analysis FAQ
What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to LMAT.
What is the valuation status of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a valuation rating of 4 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.
How profitable is LEMAITRE VASCULAR INC (LMAT) stock?
LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.
What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 45.8 and the Price/Book (PB) ratio is 6.31.
How financially healthy is LEMAITRE VASCULAR INC?
The financial health rating of LEMAITRE VASCULAR INC (LMAT) is 8 / 10.